Medipal and JCR dose first patient in JR-446 Phase I/II trial
Medipal Holdings and JCR Pharmaceuticals said the first participant was dosed in their global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.